Acurx Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
Acurx Pharmaceuticals R&D Spending Growth & History (ACXP)
Acurx Pharmaceuticals's r&d spending was $1.8M for fiscal 2025.
View full Acurx Pharmaceuticals company overviewAcurx Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.8M | −$3.6M | −66.05% |
| 2024 | 2024-12-31 | $5.4M | −$639,761 | −10.59% |
| 2023 | 2023-12-31 | $6.0M | $1.3M | +27.12% |
| 2022 | 2022-12-31 | $4.8M | $2.7M | +134.18% |
| 2021 | 2021-12-31 | $2.0M | −$172,802 | −7.84% |
| 2020 | 2020-12-31 | $2.2M | — | — |
Acurx Pharmaceuticals quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | $547,326 | +104.41% |
| Q1 2026 | 2026-03-31 | $341,468 | −$257,330 | −42.97% |
| Q4 2025 | 2025-12-31 | $281,807 | −$543,252 | −65.84% |
| Q3 2025 | 2025-09-30 | $429,691 | −$768,493 | −64.14% |
| Q2 2025 | 2025-06-30 | $524,210 | −$1.3M | −71.29% |
| Q1 2025 | 2025-03-31 | $598,798 | −$956,213 | −61.49% |
| Q4 2024 | 2024-12-31 | $825,059 | −$1.1M | −57.53% |
| Q3 2024 | 2024-09-30 | $1.2M | −$150,801 | −11.18% |
| Q2 2024 | 2024-06-30 | $1.8M | $89,196 | +5.14% |
| Q1 2024 | 2024-03-31 | $1.6M | $539,428 | +53.12% |
| Q4 2023 | 2023-12-31 | $1.9M | $509,995 | +35.60% |
| Q3 2023 | 2023-09-30 | $1.3M | −$242,058 | −15.21% |
| Q2 2023 | 2023-06-30 | $1.7M | $824,694 | +90.46% |
| Q1 2023 | 2023-03-31 | $1.0M | $196,695 | +24.02% |
| Q4 2022 | 2022-12-31 | $1.4M | $716,425 | +100.03% |
| Q3 2022 | 2022-09-30 | $1.6M | $464,071 | +41.18% |
| Q2 2022 | 2022-06-30 | $911,692 | $816,618 | +858.93% |
| Q1 2022 | 2022-03-31 | $818,888 | $726,980 | +790.99% |
| Q4 2021 | 2021-12-31 | $716,223 | — | — |
| Q3 2021 | 2021-09-30 | $1.1M | $466,995 | +70.76% |
| Q2 2021 | 2021-06-30 | $95,074 | −$305,664 | −76.28% |
| Q1 2021 | 2021-03-31 | $91,908 | — | — |
| Q3 2020 | 2020-09-30 | $659,977 | — | — |
| Q2 2020 | 2020-06-30 | $400,738 | — | — |
Acurx Pharmaceuticals r&d spending trends
Over the last five fiscal years, Acurx Pharmaceuticals's r&d spending decreased from $2.2M to $1.8M, a change of −$368,473. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acurx Pharmaceuticals source filings ↗